Pangea Announces Filing of Amended and Restated Interim Financial Statements and Management's Discussion and Analysis

Pangea Natural Foods Inc. (CSE: PNGA) has filed amended and restated interim financial statements and management's discussion and analysis for the six and nine-month periods ended April 30 and July 31, 2025, respectively. This action follows a continuous disclosure review by the British Columbia Securities Commission, with the revisions providing additional detail on the accounting policy for its Amino Innovations Inc. acquisition and the impairment indicator assessment of intangible assets and goodwill as of July 31, 2025.

Analysis

Pangea Natural Foods Inc. (PNGA) has filed amended and restated interim financial statements and Management's Discussion and Analysis (MD&A) for the six and nine-month periods ended April 30 and July 31, 2025, respectively. This action was a direct result of a continuous disclosure review conducted by the British Columbia Securities Commission (BCSC), indicating regulatory scrutiny over the company's initial financial reporting.

The amendments specifically provide additional disclosure regarding the accounting policy choice for Pangea's acquisition of Amino Innovations Inc. on April 9, 2025, and the impairment indicator assessment of intangible assets and goodwill as of July 31, 2025. These areas are critical for understanding the company's asset valuation and the financial implications of its recent M&A activity.

The regulatory intervention and subsequent restatement, coupled with a "moderately negative" sentiment score of -0.5 and a market impact score of 0.45, suggest that this event is perceived as a material concern. While Pangea operates in the clean-label foods and wellness sector, including advanced peptide therapies, the BCSC review raises questions about the robustness of the company's financial controls and reporting accuracy.

Key Decisions for Investors

• Investors should thoroughly review the amended financial statements and MD&A on SEDAR+ to understand the specific changes in accounting policies and asset valuations, particularly concerning the Amino Innovations acquisition.
• Evaluate Pangea's internal financial controls and corporate governance practices, as the BCSC review suggests potential weaknesses in financial reporting.
• Monitor for any further regulatory communications or actions from the BCSC, as ongoing scrutiny could indicate deeper systemic issues within the company's financial operations.
• Re-assess the valuation of PNGA, especially the carrying value of intangible assets and goodwill, in light of the new disclosures and potential implications for future earnings and balance sheet health.